Literature DB >> 14576143

Simulation of human gentamicin pharmacokinetics in an experimental Enterococcus faecalis endocarditis model.

Laurent Dubé1, Jocelyne Caillon, Christèle Gras-Le Guen, Cédric Jacqueline, Marie-France Kergueris, Jean-Claude Granry, Gilles Potel, Denis Bugnon.   

Abstract

Significant differences between animal and human pharmacokinetics may be responsible for the conflicting results of experimental studies. This study determined the impact of human pharmacokinetic simulation (HPS) on gentamicin activity in an Enterococcus faecalis endocarditis model. The decrease in bacterial counts was greater with HPS than with a dose-equivalent regimen without HPS.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14576143      PMCID： PMC253777          DOI： 10.1128/AAC.47.11.3663-3666.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  33 in total

1.  Variation in plasma halflife of gentamicin between species in relation to bodyweight and taxonomy.

Authors:  J K Kirkwood; J Merriam
Journal:  Res Vet Sci       Date:  1990-09       Impact factor: 2.534

2.  Pharmacokinetics of gentamicin after i.v. infusion or iv bolus.

Authors:  F Meunier; P Van der Auwera; H Schmitt; V de Maertelaer; J Klastersky
Journal:  J Antimicrob Chemother       Date:  1987-02       Impact factor: 5.790

3.  Impact of dosage schedule on the efficacy of gentamicin, tobramycin, or amikacin in an experimental model of Serratia marcescens endocarditis: in vitro-in vivo correlation.

Authors:  G Potel; J Caillon; B Fantin; J Raza; F Le Gallou; J Y Lepage; P Le Conte; D Bugnon; D Baron; H Drugeon
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

4.  In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations.

Authors:  D Andes; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

5.  Simulation of human pharmacokinetic profiles in mice, and impact on antimicrobial efficacy of netilmicin, ticarcillin and ceftazidime in the peritonitis-septicemia model.

Authors:  A U Gerber; T Stritzko; C Segessenmann; B Stalder
Journal:  Scand J Infect Dis Suppl       Date:  1990

6.  Pharmacokinetics and in vivo activity of liposome-encapsulated gentamicin.

Authors:  C E Swenson; K A Stewart; J L Hammett; W E Fitzsimmons; R S Ginsberg
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

7.  Simulation of human serum pharmacokinetics of ticarcillin-clavulanic acid and ceftazidime in rabbits, and efficacy against experimental Klebsiella pneumoniae meningitis.

Authors:  L Mizen; G Woodnutt; I Kernutt; E J Catherall
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

8.  Pharmacokinetics of gentamicin in laboratory rabbits.

Authors:  J L Curl; J S Curl
Journal:  Am J Vet Res       Date:  1988-12       Impact factor: 1.156

9.  Antimicrobial activity of gentamicin in experimental enterococcal endocarditis.

Authors:  P M Sullam; M G Täuber; C J Hackbarth; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1985-02       Impact factor: 5.191

10.  Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections.

Authors:  W A Craig; J Redington; S C Ebert
Journal:  J Antimicrob Chemother       Date:  1991-05       Impact factor: 5.790
View more
  3 in total

1.  The optimal aminoglycoside and its dosage for the treatment of severe Enterococcus faecalis infection. An experimental study in the rabbit endocarditis model.

Authors:  L Dubé; J Caillon; C Jacqueline; D Bugnon; G Potel; N Asseray
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-03-08       Impact factor: 3.267

2.  Single-dose oral amoxicillin or linezolid for prophylaxis of experimental endocarditis due to vancomycin-susceptible and vancomycin-resistant Enterococcus faecalis.

Authors:  Philippe Moreillon; Walter R Wilson; Roland Leclercq; José M Entenza
Journal:  Antimicrob Agents Chemother       Date:  2007-03-12       Impact factor: 5.191

3.  High-Precision Control of Plasma Drug Levels Using Feedback-Controlled Dosing.

Authors:  Netzahualcóyotl Arroyo-Currás; Gabriel Ortega; David A Copp; Kyle L Ploense; Zoe A Plaxco; Tod E Kippin; João P Hespanha; Kevin W Plaxco
Journal:  ACS Pharmacol Transl Sci       Date:  2018-10-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.